Results of The AREDS2 HOME Study of Notal Vision’s Home Monitoring Device for AMD Announced
December 2, 2013
We’ve previously blogged about the ForeseeHome AMD Monitor device from Notal Vision.
As reported at the Retinal Subspecialty Meeting at this year’s AAO Meeting, the results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, showed that participants at high risk for developing choroidal neovascularization (CNV) using the ForeseeHome monitoring device strategy had significantly better preservation of their visual acuity at the time of CNV detection than the control group of participants who were only using standard care methods (the Amsler grid) to self monitor their AMD for progression. The study’s Data Safety and Monitoring Committee recommended early termination of the study on April 2, 2013 based on superior vision outcomes among the participants randomly assigned to use the home device.
To read more, follow this link.
Comments
Jump down to form below to submit your own comments
